Search Results

You are looking at 1 - 3 of 3 items for

  • Author: C. M. Gillespie x
  • Refine by access: All content x
Clear All Modify Search
A A Martin
Search for other papers by A A Martin in
Google Scholar
PubMed
Close
,
C M Gillespie
Search for other papers by C M Gillespie in
Google Scholar
PubMed
Close
,
L Moore
Search for other papers by L Moore in
Google Scholar
PubMed
Close
,
F J Ballard
Search for other papers by F J Ballard in
Google Scholar
PubMed
Close
, and
L C Read
Search for other papers by L C Read in
Google Scholar
PubMed
Close

Abstract

The effect of insulin-like growth factor-I (IGF-I) administration on body weight gain and the rate of recovery of renal function was investigated in rats following an acute episode of renal ischaemia. Since the des(1–3)IGF-I and LR3IGF-I variant forms of IGF-I have been shown to be more potent than IGF-I, their effects were also examined. Acute renal failure was produced in male Sprague–Dawley rats by clamping both renal arteries for 45 min. Treatment was commenced at the time of renal artery occlusion with vehicle (0·1 mol acetic acid/l; control group), IGF-I (2·0 mg/kg per day), des(1–3)IGF-I (2·0 mg/kg per day) or LR3IGF-I (1·5 mg/kg per day) by s.c. osmotic pump, and continued for 7 days, with rats being held in metabolism cages. Glomerular filtration rate (GFR) was estimated by the use of 51Cr-EDTA continuously infused i.p. via osmotic pump. Following the episode of renal ischaemia, body weight gain and nitrogen retention were significantly improved in all three peptide-treated groups, and serum urea concentrations were reduced in the groups treated with IGF-I and des(1–3)IGF-I. However, there was no evidence of the variants having any increased potency over the growth effects of IGF-I itself. GFR was significantly reduced, urine output was increased and urinary concentrating ability was reduced in all groups compared with normal rats, with no significant effect of the IGF peptides being apparent.

A closer examination of the acute effects of LR3IGF-I on renal function was undertaken by measuring GFR for 3 days before and 3 days after renal ischaemia in two groups of rats, treated for the latter 3 days with either vehicle (controls) or LR3IGF-I (1·5 mg/kg per day). LR3IGF-I treatment following renal ischaemia resulted in a significantly greater fall in GFR than in controls, urinary osmolality was also significantly reduced, and fractional excretion of sodium was increased. In addition, there was histological evidence of a greater degree of tubular epithelial calcification in the kidneys of the rats treated with LR3IGF-I.

This study showed that administration of IGF peptides at doses sufficient to cause significant improvement in anabolic status did not improve renal function in rats following an acute episode of renal ischaemia. Indeed the LR3IGF-I variant of IGF-I had a deleterious effect on renal function in the early stage of the recovery period.

Journal of Endocrinology (1994) 140, 23–32

Restricted access
L. C. Read
Search for other papers by L. C. Read in
Google Scholar
PubMed
Close
,
F. M. Tomas
Search for other papers by F. M. Tomas in
Google Scholar
PubMed
Close
,
G. S. Howarth
Search for other papers by G. S. Howarth in
Google Scholar
PubMed
Close
,
A. A. Martin
Search for other papers by A. A. Martin in
Google Scholar
PubMed
Close
,
K. J. Edson
Search for other papers by K. J. Edson in
Google Scholar
PubMed
Close
,
C. M. Gillespie
Search for other papers by C. M. Gillespie in
Google Scholar
PubMed
Close
,
P. C. Owens
Search for other papers by P. C. Owens in
Google Scholar
PubMed
Close
, and
F. J. Ballard
Search for other papers by F. J. Ballard in
Google Scholar
PubMed
Close

ABSTRACT

The effects of insulin-like growth factor-I (IGF-I) on the gut of 150 g dexamethasone-treated rats were compared with those of two analogues with reduced affinity for IGF-binding proteins, des(1–3)IGF-I and LR3IGF-I, an N-terminal-extended variant. Administration of IGF-I for 7 days to rats made catabolic by co-treatment with dexamethasone induced a dose-dependent increase in total gut weight, with the highest dose of IGF-I (695 μg/day) increasing gut weight by up to 60%, and gut weight as a fraction of body weight by up to 32%. Effects were apparent in all regions of the gut examined, including the stomach, small intestine and colon. Histological and biochemical analyses of the intestine showed that cross-sectional mass, rather than gut length, was increased, and proportional increases in wet weight, protein and DNA content per unit length were measured in both the mucosa and muscularis layers. The rate of duodenal protein synthesis measured on day 7 of treatment was not increased by IGF-I treatment. The IGF-I analogues had qualitatively similar effects to IGF-I, but were consistently severalfold more potent, providing evidence that IGF-binding proteins reduce the biological activity of exogenous IGF-I in the gut. The results indicate that the gut is one of the most sensitive IGF-I target tissues, and that potency in vivo correlates with a reduced interaction with IGF-binding proteins.

Journal of Endocrinology (1992) 133, 421–431

Restricted access
KM Kelley
Search for other papers by KM Kelley in
Google Scholar
PubMed
Close
,
KE Schmidt
Search for other papers by KE Schmidt in
Google Scholar
PubMed
Close
,
L Berg
Search for other papers by L Berg in
Google Scholar
PubMed
Close
,
K Sak
Search for other papers by K Sak in
Google Scholar
PubMed
Close
,
MM Galima
Search for other papers by MM Galima in
Google Scholar
PubMed
Close
,
C Gillespie
Search for other papers by C Gillespie in
Google Scholar
PubMed
Close
,
L Balogh
Search for other papers by L Balogh in
Google Scholar
PubMed
Close
,
A Hawayek
Search for other papers by A Hawayek in
Google Scholar
PubMed
Close
,
JA Reyes
Search for other papers by JA Reyes in
Google Scholar
PubMed
Close
, and
M Jamison
Search for other papers by M Jamison in
Google Scholar
PubMed
Close

Emerging early in chordate evolution, the IGF-regulatory axis diverged from an insulin-like predecessor into a vertebrate regulatory system specializing in cell growth activation and allied anabolic functions. Essential to the divergence of the IGF and insulin systems was an early presence of soluble IGF-binding proteins (IGFBPs), which bind IGF peptides at much higher affinity than that of the insulin receptor but at comparable affinities to that of the IGF receptor. IGFBPs have no homology with IGF receptors. Instead, IGFBPs are a derived group of proteins within a superfamily of cysteine-rich growth factors, whose members are found throughout the animal taxa. While blocking IGF actions through the insulin receptor is a fundamental role, IGFBPs evolved within the vertebrate line into centralized, 'integrators' of the endocrine growth-regulatory apparatus. IGFBPs have substantial influences on the distribution and bioavailability of IGF peptides in the cellular and physiological environments, but they have a variety of other properties. The six principal mammalian IGFBPs exhibit an array of specialized properties that appear to be derived from a complex evolutionary history (including cell membrane association, interaction with proteins that post-translationally modify them, direct IGF-independent effects on cells, and others) and they are regulated by a diversity of 'outside' factors (e.g. other hormones, metabolic status, stress). Thus, IGFBPs are multifunctional integrators having diverse physiological 'agendas'. Much less is known about IGFBPs and their properties in the other vertebrate taxa. Increasingly, however, it is being recognized that they play equally important endocrine roles, in both conserved and non-conserved ways, when compared with those currently defined in mammals. This review highlights selected 'comparative aspects' in current IGFBP research, in an attempt to view this essential group of endocrine regulators from a wider, biological perspective.

Free access